Novo Nordisk’s strategy to grow beyond metabolic diseases includes expanding into adjacent areas such as cardiovascular disease. Acquiring Cardio Pharmaceuticals adds a novel RNA-based therapy that is a potential heart failure treatment.
Novo Nordisk Expands Cardio Reach by Buying Heart Drugs Biotech Cardior
